Zhang Wenping, Gao Shenghao, Yang Yuanjian, Tian Cuijie, Li Cheng, Hu Xin'gang, Liu Hui, Zhao Zhigang, Liu Hongmei, Zhang Xiaoju, Cheng Jianjian
Department of Respiratory and Critical Care Medicine, People's Hospital of Henan Province, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou 450003, Henan, China. Corresponding author: Cheng Jianjian, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Feb;35(2):130-134. doi: 10.3760/cma.j.cn121430-20220531-00515.
To explore the predictive value of HACOR score [heart rate (H), acidosis (A), consciousness (C), oxygenation (O), and respiratory rate (R)] on the clinical outcome of non-invasive positive pressure ventilation in patients with pulmonary encephalopathy due to chronic obstructive pulmonary disease (COPD).
A prospective study was conducted. The patients with COPD combined with pulmonary encephalopathy who were admitted to Henan Provincial People's Hospital from January 1, 2017 to June 1, 2021 and initially received non-invasive positive pressure ventilation were enrolled. Besides non-invasive positive pressure ventilation, standard medical treatments were delivered to these patients according to guidelines. The need for endotracheal intubation was judged as failure of non-invasive ventilation treatment. Early failure was defined as the need for endotracheal intubation within 48 hours of treatment, and late failure was defined as the need for endotracheal intubation 48 hours and later. The HACOR score at different time points after non-invasive ventilation, the length of intensive care unit (ICU) stay, the total length of hospital stay, and the clinical outcome were recorded. The above indexes of patients with non-invasive ventilation were compared between successful and failed groups. The receiver operator characteristic curve (ROC curve) was drawn to evaluate the predictive effect of HACOR score on the failure of non-invasive positive pressure ventilation in the treatment of COPD with pulmonary encephalopathy.
A total of 630 patients were evaluated, and 51 patients were enrolled, including 42 males (82.35%) and 9 females (17.65%), with a median age of 70.0 (62.0, 78.0) years old. Among the 51 patients, 36 patients (70.59%) were successfully treated with non-invasive ventilation and discharged from the hospital eventually, and 15 patients (29.41%) failed and switched to invasive ventilation, of which 10 patients (19.61%) were defined early failure, 5 patients (9.80%) were late failure. The length of ICU and the total length of hospital stay of the non-invasive ventilation successful group were significantly longer than those of the non-invasive ventilation failure group [length of ICU stay (days): 13.0 (10.0, 16.0) vs. 5.0 (3.0, 8.0), total length of hospital stay (days): 23.0 (12.0, 28.0) vs. 12.0 (9.0, 15.0), both P < 0.01]. The HACOR score of patients at 1-2 hours in the non-invasive ventilation failure group was significantly higher than that in the successful group [10.47 (6.00, 16.00) vs. 6.00 (3.25, 8.00), P < 0.05]. However, there was no significant difference in HACOR score before non-invasive ventilation and at 3-6 hours between the two groups. The ROC curve showed that the area under the ROC curve (AUC) of 1-2 hour HACOR score after non-invasive ventilation for predicting non-invasive ventilation failure in COPD patients with pulmonary encephalopathy was 0.686, and the 95% confidence interval (95%CI) was 0.504-0.868. When the best cut-off value was 10.50, the sensitivity was 60.03%, the specificity was 86.10%, positive predictive value was 91.23%, and negative predictive value was 47.21%.
Non-invasive positive pressure ventilation could prevent 70.59% of COPD patients with pulmonary encephalopathy from intubation. HACOR score was valuable to predict non-invasive positive pressure ventilation failure in pulmonary encephalopathy patients due to COPD.
探讨HACOR评分[心率(H)、酸中毒(A)、意识(C)、氧合(O)和呼吸频率(R)]对慢性阻塞性肺疾病(COPD)所致肺性脑病患者无创正压通气临床结局的预测价值。
进行一项前瞻性研究。纳入2017年1月1日至2021年6月1日在河南省人民医院住院并初始接受无创正压通气的COPD合并肺性脑病患者。除无创正压通气外,这些患者均按照指南给予标准药物治疗。将气管插管需求判定为无创通气治疗失败。早期失败定义为治疗后48小时内需要气管插管,晚期失败定义为治疗48小时及以后需要气管插管。记录无创通气后不同时间点的HACOR评分、重症监护病房(ICU)住院时间、总住院时间及临床结局。比较无创通气成功组与失败组患者的上述指标。绘制受试者工作特征曲线(ROC曲线),以评估HACOR评分对COPD合并肺性脑病患者无创正压通气治疗失败的预测效果。
共评估630例患者,纳入51例,其中男性42例(82.35%),女性9例(17.65%),中位年龄70.0(62.0,78.0)岁。51例患者中,36例(70.59%)无创通气治疗成功并最终出院,15例(29.41%)失败并转为有创通气,其中10例(19.61%)为早期失败,5例(9.80%)为晚期失败。无创通气成功组的ICU住院时间和总住院时间均显著长于无创通气失败组[ICU住院时间(天):13.0(10.0,16.0) vs. 5.0(3.0,8.0),总住院时间(天):23.0(12.0,28.0) vs. 12.0(9.0,15.0),均P < 0.01]。无创通气失败组患者1 - 2小时的HACOR评分显著高于成功组[10.47(6.00,16.00) vs. 6.00(3.25,8.00),P < 0.05]。然而,两组在无创通气前及3 - 6小时的HACOR评分无显著差异。ROC曲线显示,无创通气后1 - 2小时HACOR评分预测COPD合并肺性脑病患者无创通气失败的ROC曲线下面积(AUC)为0.686,95%置信区间(95%CI)为0.504 - 0.868。最佳截断值为10.50时,灵敏度为60.03%,特异度为86.10%,阳性预测值为91.23%,阴性预测值为47.21%。
无创正压通气可使70.59%的COPD合并肺性脑病患者避免插管。HACOR评分对预测COPD所致肺性脑病患者无创正压通气失败有价值。